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OBJECTIVES: The rapid growth in opioid therapy for non-cancer pain has 
occurred without an adequate appreciation of the consequences of this growth. 
Few studies provide patient-centered evidence that can be used to inform the 
current proposed standards for efficacious (safe and effective) opioid prescribing 
in non-cancer pain. Furthermore, different terms may be used interchangeably 
in the literature to refer to opioid-taking behaviors, resulting in imprecise or 
vague interpretation of existing evidence. We therefore sought to explore 
patterns of opioid-taking behavior and their biopsychosocial-spiritual 
determinants in African-American adults with sickle cell disease (SCD). 
METHODS: We conducted a multi-phase mixed methods study which included 
quantitative and semi-structured qualitative interviews. A grounded theory 
approach was used to analyze the data. RESULTS: The final sample consisted of 
11 men and 10 women, average age 36 years. Qualitative thematic analysis 
uncovered several patterns of opioid-taking behavior and several related 
biopsychosocial- spiritual phenomena, some hypothesized and some not. These 
patterns and phenomena portrayed a new six-domain conceptual framework 
that addresses the complex individual, relational, environmental, cultural, and 
system issues surrounding opioid taking-behavior in SCD, and provides a 
roadmap for future research: 1) Pain and its consequences; 2) Prescribed opioid-
taking behaviors and their biopsychosocial consequences; 3) Effects of 
biopsychosocial determinants on opioid-taking behaviors; 4) Aberrant behavior; 
5) Physician prescribing behaviors and attitudes; and 6) Hypothetical targets for 
interventions to improve prescribing and opioid taking-behaviors. Further, the 
data portrayed explanatory factors that could be classified into various levels or 
domains based on models proposed in prior research. Factors included within-
patient (biological, spiritual, psychological), and social and environmental (social 
support, provider relationships, institutional norms, culture, legal and 
governmental policy) domains. CONCLUSIONS: The explored domains offer rich 
guidance toward understanding multi-level explanatory effect of pain, its 
pharmacotherapy, and medication taking behaviors on SCD individual’s health 
that simultaneously bridges all health care domains.  
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OBJECTIVES: Many questions surround opioid use for non-cancer pain, but little 
has been published about behavioral patterns of taking opioids in these conditions. 
The objective of this abstract is to report partial results: patterns of opioid use, and 
effects of biopsychosocial-spiritual determinants on opioid-taking behaviors. 
METHODS: As part of a multiphase, mixed-method study, we conducted wide-
ranging quantitative and semi-structured, qualitative interviews of African-
American adults with sickle cell disease (SCD). The final sample consisted of 11 
men and 10 women, average age 36 years, from various socioeconomic and 
educational levels. We used a grounded theory approach to analyze the data. 
RESULTS: Qualitative thematic analysis revealed three phenomena 1) SCD patients 
exhibited various opioid-taking behavior patterns including adherence, overuse, 
underuse, and erratic use; 2) A wide variety of biopsychosocial-spiritual factors 
hindered or motivated opioid use: pain intensity; side effects; fear of addiction; 
perceived stigma or judgment by others; senses of responsibility, productivity, 
hopelessness, or obligation; stress; social role pressure; social desirability; bullying; 
and anticipatory fear of adverse outcomes; and 3) Behaviors varied based on the 
time of day, week, month, or year, and based on context at times of doses. 
CONCLUSIONS: In summary, we found that contextual factors may drastically 
affect opioid-taking behaviors. Together, These uncovered phenomena raise new 
hypotheses that may challenge current theories and models of medication-taking 
behaviors and methods of assessing adherence. These hypotheses call for a new 
round of research on opioid-taking behavior, and need to be rigorously tested in 
future research.  
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OBJECTIVES: To utilize Conjoint Analysis to evaluate the relative importance of 
extrinsic and intrinsic product attributes in OTC analgesic purchase and 
examine feature trade-offs in product choice. METHODS: A cross-sectional 
questionnaire survey with profile cards and convenience sample. Consumers 
shopping at three New York City pharmacies and two convenience stores were 
recruited and asked to rank order profile cards based on their preference for 
different combinations of product features. Conjoint analysis employing 
fractional factorial design with an orthogonal array was used to generate 11 
profile cards each for a pair of product attributes (extrinsic and intrinsic). 
Attributes were analyzed separately and combined, along with multiple levels 
within each attribute. All feature configurations: price, brand image & promotion 
(extrinsic); and effectiveness, side effects & dose regimen (intrinsic); were 
assigned average importance scores and Part-Worth utility scores for all levels 
within. Importance of each profile relative to other profiles within and across the 
two attributes was determined. RESULTS: The pilot phase of the study (n=32) 
showed significant Kendall’s Tau correlation among profile cards (0.873), 
confirming instrument validity. In the main study sample (n=103), with respect 
to extrinsic attributes, Part-Worth Utility scores indicated price as being the most 
preferred attribute (1.456) compared to brand image (-1.469) and promotion 
(0.013). With respect to intrinsic attributes, dose regimen was preferred (1.097) 
over effectiveness (-0.257), followed by side effects (-0.838). The percentage 
preference analysis indicated a greater influence of extrinsic features on 
consumer product choice compared to intrinsic features (57.36% vs. 42.64%). 
CONCLUSIONS: Overall, in decisions regarding choice of a right analgesic 
product, extrinsic attributes matter more to the consumer than intrinsic 
features. Brand image and promotional aspects are traded off in favor of price, 
and dosing convenience is strongly preferred over side effects profile and 
product effectiveness.  
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OBJECTIVES: Hemophilia A is a rare, inherited bleeding disorder in which the 
affected individual lacks or has limited production of coagulation factor VIII 
(FVIII), resulting in the inability of the blood to clot normally. Treatment typically 
involves life-long replacement of FVIII through intravenous infusions to stop or 
prevent spontaneous or traumatic bleeds. However, FVIII storage and stability 
remain a constant challenge. Obtaining patients’ and caregivers’ perspectives is 
critical to disease management, particularly with rare conditions. A web-based 
survey was developed to assess hemophilia A patients’ and caregivers’ 
preferences around FVIII storage and stability attributes. METHODS: Individuals 
with hemophilia A and caregivers of minor children with hemophilia A from 
local and national hemophilia support groups in the United States and Canada 
were invited to complete a web-based survey assessing patients’ FVIII ordering, 
usage, and storage routines. RESULTS: Of the 145 individuals who responded to 
the survey invitation, 101 individuals (67% caregivers [82% female]) completed 
the survey (70%). Nearly half (48%) of respondents ordered FVIII monthly, and 8% 
reported often having FVIII vials expire before their use. Challenges to storing 
FVIII included refrigeration when traveling (28%) and carrying an insulated tote 
bag (27%). More than half (54%) preferred a new FVIII product with longer storage 
at room temperature. The majority (80%) indicated preference for a FVIII product 
that could be stored at a higher room temperature for longer durations, primarily 
for ease in traveling, keeping more factor at home, and having easy access when 
needed. CONCLUSIONS: This web-based study provides a unique perspective 
from patients and caregivers on treatment attributes that are important to this 
population. There is a need for an improved FVIII product that offers more 
convenience and faster access to patients in daily life and while traveling. 
Additionally, flexibility in storage potentially could reduce the frequency of FVIII 
wastage.  
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OBJECTIVES: To examine the effect of 8% capsaicin patch on change in “usual 
pain” using a modified PNRS (Pain Numeric Rating Scale). A secondary objective 
was to examine utility scores assessed by the EQ-5D-3L. METHODS: Adult 
patients diagnosed with peripheral neuropathic pain (excluding diabetic 
polyneuropathy) were included. Each patient was eligible to receive up to two 
treatments. Parameters: PNRS, patient’s pain intensity over the past 24 hours: 
usual, highest, lowest and right now EQ-5D-3L Size of treated area RESULTS: A 
total of 412 patients were included, 382 patients completed first treatment 
period, 266 with partial peripheral nerve injury; 51 with post herpetic neuralgia 
(PHN); 19 with polyneuropathy and 46 with other painful neuropathies. Fifty-
nine percent were women, mean age was 53 years (range 18–88). A total of 184 
patients were given a re-treatment and 181 patients completed the re-treatment 
period. PNRS: Usual pain intensity over the past 24 hours (maximum pain 
reduction at any time point) decreased from 6.3 to 4.4 (p < 0.001) and at re-
treatment from 6.3 to 5.0 (p < 0.001). Mean EQ-5D health score was 0.33 (SD 0.32) 
at baseline (range -0.38-1.00). During the post-treatment period the mean change 
was 0.25 (SD 0.29), (p < 0.001). At baseline, 58% of all patients reported “Extreme 
Problem” in the pain/discomfort dimension and corresponding figures for the 
post-treatment period was 38%. Mean EQ-5D health score was 0.54 (SD 0.32) at 
start of re-treatment (range -0.26-1.00). During the post-re-treatment period the 
mean change was 0.17 (SD 0.28 (p < 0.001). The area treated had at baseline a 
median size of 180 cm2 and at re-treatment 160 cm2. CONCLUSIONS: In this 
population of patients with peripheral neuropathic pain and a markedly reduced 
QoL, treatment of capsaicin 8% significantly reduced patients’ experience of 
“usual pain” and improved short-term HRQoL evaluated by EQ-5D-3L.  
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